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Pharmacoepidemiology involves development of new models to predict safety in the development stages of
pharmaceutical products, development of various guidelines and policy related to clinical trials, pharmacovigilance,
establishment and implementation of risk management in postmarketing studies, and cost-effectiveness research
in medical and social welfare sectors. Evaluations of safety, efficacy, and costs of pharmaceutical products must
be developed in a different way. More recently, “big data” in medicine have become the driving force behind
epidemiological studies that attempt to solve questions in the clinical setting. Furthermore, it is important to pursue
cost-effectiveness considering the government’s financial condition. Epidemiologic and economic research utilizing
epidemiological data linked to cost data will provide scientific evidence for appropriate distribution of health resources.
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Pharmacoepidemiology is a novel research area established
in the 1980s. Its core lies at the intersection of two subspe-
cialties: clinical epidemiology and clinical pharmacology
[1]. It covers a wide area including pharmacovigilance, re-
search on the efficacy and safety of drugs [2], regulatory
science with assessment of the safety of pharmaceutical
products, comparative effectiveness research (CER), cost-
effective analysis (CEA), and guideline assessment [3]. Few
are experienced in these fields, so more researchers and
promotion of these areas are desirable.
The typical focus of pharmacoepidemiology is pharma-
covigilance or postmarketing surveillance (PMS), also called
phase IV trials. The gold standard for clinical research is
randomized clinical trials (RCTs) [4]. However, clinical
trials have strict inclusion criteria and rarely include elderly
patients, pregnant women, and those with multiple comor-
bidities. Moreover, the duration is relatively short and the
number of subjects are limited [5]. Therefore, we cannot
expect these trials to accurately reflect actual drug use in
real-life clinical settings. Observational studies with longer
follow-up times, inclusion of patients with concomitant
illnesses, and larger patient numbers may better identify* Correspondence: kawakami.koji.4e@kyoto-u.ac.jp
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unless otherwise stated.clinically important adverse events compared with RCTs [6].
It is essential to perform pharmacoepidemiological studies
to identify adverse effects and drug efficacy in the real-world
setting using a large-scale medical database [7].
Review
1. Classification of medical databases
The databases that are available for use in pharmacoepi-
demiological studies include administrative claims data-
base, pharmacy dispensing database, electronic medical
records, and care information. In Japan, large-scale med-
ical databases were constructed by the government in the
past decade. The Ministry of Health, Labour and Welfare
(MHLW) developed a national claims and health checkup
database (NDB) and the Sentinel project to detect adverse
drug reactions based on the medical records of large hos-
pitals [8,9]. In addition, the Japan Surgical Society devel-
oped the National Clinical Database (NCD) as a patient
registry to identify drug efficacy and outcomes [10].
2. Medical databases in Japan
Claims database
The largest claims database available for academic and
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from approximately 2,300,000 people who belong to a
health insurance provider for company employees. It in-
cludes data from inpatients, outpatients, and pharmacy
claims as well as Diagnosis Procedure Combination (DPC)
data collected every month, and all items listed together
are placed into the database. Secondary data are not only
utilized by the health insurance union but also by pharma-
ceutical companies with secondary use permission, thereby
contributing to epidemiological studies [12]. The advantage
of the claims database is that it can provide diagnosis and
treatment information even if a patient switches to another
clinic or hospital, but it cannot provide examination results
or clinical outcomes.
The DPC is a Japanese case-mix classification system
launched in 2002 by the MHLW and is linked to a
lump-sum payment system. Approximately 1,500 hospi-
tals use DPC in acute medical care, and a database based
on DPC is provided by Medical Data Vision (MDV),
Co., covering 143 facilities that represent approximately
10% of institutions in Japan. This database is an elec-
tronic health records-based database that contains an-
onymous information from health insurance claims of
about 8.5 million patients from April 2008 to 2014. It
contains patient information such as age, sex, relevant
medical department, disease name on the prescription,
and information on medications, surgery, injections, tests,
diagnosis in DPC claims, patient outcomes, and results
of blood tests and other laboratory tests [13]. Detailed
treatment history is included in the DPC data in a
particular hospital.Pharmacy dispensing database
A few Japanese companies that run pharmacies such as
Nihon Chouzai Co. also maintain their own administra-
tive database, which includes information on dispensing
drug formulas. Our research group combines data from
four companies that own pharmacies to analyze approxi-
mately 20 million prescriptions per year. This dataset
enables us to identify patterns in drug prescriptions
nationwide and patient adherence to drugs [14].Other hospital databases
The Platform for Clinical Information Statistical Analysis
(CISA) is another medical database that collects claims
data from 14 Japanese national university hospitals. An-
onymous medical records in each institution are integrated
and analyzed. Establishing a linkage with laboratory results
data is currently underway. A pharmacoepidemiological
study of the patterns of prescription of osteoporosis drugs
for patients on glucocorticoids or those with lifestyle-related
disease-related in Japan has been performed utilizing the
CISA database [15].Methodological and ethical considerations
Because each database has different characteristics in
terms of clinical and administrative records, researchers
performing pharmacoepidemiological studies need to
clearly recognize the strengths and weaknesses of each
database [16]. According to the Ethical Guidelines on
Biomedical Research Involving Human Subjects by
Ministry of Education, Culture, Sports, Science and
Technology and Ministry of Health, Labour and Welfare
[17], pharmacoepidemiological studies of medical data-
bases would be classified as research based on pre-existing
material and information without any invasions and inter-
ventions. The guidelines require a study protocol which
includes design and conduct of the study as well as ethical
issues such as handling of privacy information, disclosure
of the study and conflict of interest, but written informed
consent is not mandatory for studies of medical databases.
3. Pharmacoepidemiological studies in Japan
Drug safety study
The first example of a pharmacoepidemiological study in
Japan is a drug safety study of palivizumab, an anti-
respiratory syncytial virus humanized monoclonal antibody
used for prophylaxis against severe lower respiratory tract
infection in children [18]. It was difficult to conduct a
comparative study in Japan because the clinical guideline,
universal health insurance system, and subsidy for palivizu-
mab permit prescription of the drug to almost all patients
who need it. The researchers therefore studied the adverse
events of palivizumab by applying a novel study design
called the self-controlled case series method. The aims
of the study were to clarify the advantages and difficulties
of the self-controlled case series method compared with
cohort studies, and to explore the impact of different defi-
nitions of periods and events used for the analysis on the
results. The database used in this example consisted of
anonymized records from 16 DPC hospitals in Japan pro-
vided by MDV. A total of 70,771 eligible children from
neonates to those aged 5 years were identified and 641 pa-
tients were treated by palivizumab. The incidence rate ra-
tios for diarrhea, bronchitis, and eczema were 3.0 (95%
confidence interval [CI] 1.7–5.4), 10.3 (95% CI 8.0–13.2),
and 16.9 (95% CI 12–23), respectively, but results varied
greatly depending on the definitions of the periods and
events used for the analysis. The researchers concluded
that the self-controlled case series method using adminis-
trative databases could be a useful tool in pharmacoepide-
miological studies of children, but these studies should be
viewed as hypothesis-generating rather than confirmatory.
Drug utilization study using a claims database
Administrative databases also provide an important means
to describe prescription patterns [12] and utilization trends
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scription patterns and trends for antirheumatic drug use
in Japanese patients with rheumatoid arthritis (RA) and
examined whether these patients are being treated
according to EULAR recommendations and ACR guide-
lines [12]. The researchers used a large-scale claims
database managed by JMDC containing the claims of
employee health insurance recipients [1,11] to identify
5,126 users of antirheumatic drugs with diagnosis codes
of RA. The number of patients who received disease-
modifying antirheumatic drugs (DMARDs) including
biologics as initial therapy was 629 (12.3%), while the
others received non-DMARD therapy only, although
the guidelines in the USA and Europe recommend ag-
gressive first-line treatment. During the study period,
the use of methotrexate and biologics as first-line drugs
increased from 1.9% to 8.0% and from zero to 1.6%, re-
spectively (p < 0.001 for both), while the use of non-
steroidal anti-inflammatory drugs decreased (p = 0.004).
These findings suggest that many early RA patients in
Japan do not receive aggressive treatment, although this
prescribing practice is gradually changing to better comply
with clinical recommendations.
Drug utilization study using pharmacy dispensing
databases
Cancer care in Japan has rapidly changed from in-hospital
care to outpatient care and from in-hospital prescription
to external prescription at pharmacies. Therefore, Taki-
zawa et al. studied the use of oral anticancer medicines in
pharmacies that accept insurance [unpublished data]. This
study analyzed the dispensing databases of 489 pharma-
cies that are managed by two major pharmacy chains in
Japan. A total of 31,628 patients who received oral anti-
cancer medicines between June 1, 2011 and May 31, 2012
with 156,904 prescriptions were identified in the databases.
These patients received hormone therapy (n = 19,899
[62.9%]), anti-metabolic medicines (n = 9,002 [28.5%]), mo-
lecularly targeted medicines (n = 1716 [5.4%]), alkylating
compound medicines (n = 839 [2.7%]), microtubule inhibi-
tors (n = 148 [0.5%]), and immune-suppressing agents (n =
24 [0.1%]). These findings suggest not only increasing use
of oral anticancer medicines in pharmacies that accept
insurance but also the importance of pharmacy–clinic
cooperation in clinical practice. Patients in the phar-
macy dispensing dataset are unique because they are all
outpatients, but the data may include uninsured dis-
pensing, unlike the claims databases.
4. Health technology assessment and
pharmacoepidemiology
Health technology assessment (HTA) is a method of
evidence synthesis that considers evidence regardingclinical effectiveness, safety, and cost-effectiveness, and
when the term is considered in a broad sense it includes
social, ethical, and legal aspects of the use of health
technologies [19]. There are processes such as evidence-
based medicine (EBM), cost-benefit analysis (CBA), and
CER in HTA. In the practice of EBM, HTA considers
evidence regarding the efficacy and effectiveness of inter-
ventions as well as patient values and is mainly con-
cerned with individual patients’ decisions, but it is also
useful for developing clinical guidelines for individual
patients. Analyzing the total cost of medical intervention
and its benefit depends on CBA. For example, suppose
that medical treatments A and B for a specific disease
both have a constant curative effect, statistically analyzing
the effectiveness of both from the perspective of costs
constitutes CER. There are techniques such as Markov
models for use in epidemiologic studies. In evaluating an-
ticancer treatment, two indices may be used for CER:
quality-adjusted life year (QALY) related to quality of life
for the duration of survival of the patient and additional
expenses to obtain one more QALY (incremental cost-
effectiveness ratio [ICER]) from conventional therapy. A
major use of HTA should include benefit–harm assessment
and economic evaluation. Pharmacoepidemiology plays
an important role in assessing the cost-effectiveness of
pharmaceutical products.
The efficacy of statin for people without cardiovascular
disease has been established in clinical trials. Nonethe-
less, it is unclear for whom and when statin treatment
should be initiated with regard to absolute risk reduction
of cardiovascular disease and cost-effectiveness of long-
term statin therapy. Onishi et al. [20] performed cost-
effectiveness analysis of statin therapy in populations with
different risk factors. The incidence of acute myocardial
infarction was estimated using a risk prediction formula
derived from a cohort study in Japan, the Japan Arterio-
sclerosis Longitudinal Study–Existing Cohorts Combined
(JALS-ECC). The incremental cost-effectiveness ratios of
pravastatin therapy compared with no-drug therapy over
a lifetime were 9,677,000 yen per QALY for 55-year-old
men and 8,648,000 yen per QALY for 65-year-old men
with cardiac risk factors of diabetes mellitus, hyperten-
sion (grade II), and smoking, and statin therapy was
not cost-effective compared with no-drug therapy in all
evaluated subgroups.
Conclusions
Pharmacoepidemiological studies utilizing various data-
bases contribute to the medical community by improv-
ing medical services and drug safety; assist the industry
in identifying unmet needs; aid regulatory agencies in
their assessment of efficacy and safety profile of drugs;
and help stakeholders including healthcare providers to
analyze the cost-effectiveness of drugs. The guideline for
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Pharmaceuticals and Medical Devices Agency in 2014
[21]. This guideline is intended to assist not only investiga-
tors of pharmaceutical companies with issues pertaining to
the planning, conduct, and evaluation of pharmacoepide-
miological studies, but also academic researchers by pro-
moting careful study design with appropriate utilization of
medical databases. Establishment of medical databases for
the purpose of epidemiological research will be useful, and
robust investigations in a variety of therapeutic areas will
expand the frontiers of pharmacoepidemiology.
Abbreviations
CER: Comparative effectiveness research; CEA: Cost-effective analysis;
PMS: Postmarketing surveillance; RCTs: Randomized clinical trials;
NDB: National Claim insurance and health checkup database; NCD: National
Clinical Database; JMDC: Japanese Medical Data Center; DPC: Diagnosis
Procedure Combination; CISA: Clinical Information Statistical Analysis;
RA: Rheumatoid arthritis; DMARDs: Disease-modifying antirheumatic drugs;
MTX: Methotrexate; NSAIDs: Non-steroidal anti-inflammatory drugs;
HTA: Health technology assessment; EBM: Evidence-based medicine;
CBA: Cost-benefit analysis; QOL: Quality of life; QALY: Quality-adjusted life
year; ICER: Incremental cost-effectiveness ratio.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors contributed to the literature review and drafting of the
manuscript, and approved the final version of the manuscript.
Received: 10 February 2015 Accepted: 14 April 2015
References
1. Porta M. A Dictionary of Epidemiology. 5th ed. New York, NY: Oxford
University Press; 2008.
2. Kita F, Shibata Y, Yorifuji T, Nakahata T, Kawakami J, Kawakami K.
Prescription trends for treatment of paediatric gastroenteritis at a Japanese
hospital between 1997 and 2007. J Clin Pharm Ther. 2010;35:87–92.
3. Urushihara H, Kawakami K. Development Safety Update Reports and
Proposals for Effective and Efficient Risk Communication. Drug Saf.
2010;33:341–52.
4. Hahn OM, Schilsky RL. Randomized controlled trials and comparative
effectiveness research. J Clinical Oncol. 2012;30:4194–201.
5. Yasmina A, Deneer VH, der Zee AH M-v, van Staa TP, de Boer A, Klungel OH.
Application of routine electronic health record databases for pharmacogenetic
research. J Intern Med. 2014;275:590–604.
6. Silverman SL. From randomized controlled trials to observational studies.
Am J Med. 2009;122:114–20.
7. WHO: The UPPSALA MONITERING CENTER. Available at http://www.who-
umc.org/DynPage.aspx?id=115092&mnl=7347&mn2=7252&mn3=7613
&mn4=7614, accessed March 27, 2015
8. Ministry of Health, Labour and Welfare: “Iryou Service no Shitsu no Koujou
tou no tameno Reseputo Jouhou tou no Katsuyou ni kansuru Kentoukai”
Houkokusho. Available at http://www.mhlw.go.jp/shingi/2008/01/dl/s0130-
16a.pdf, accessed March 27, 2015
9. Ministry of Health, Labour and Welfare: “Denshika sareta Iryou Jouhou
Database no Katsuyou niyoru Iyakuhin tou no Anzen Anshin ni kansuru
teigen (Nihon no Sentinel Project) nitsuite”. Available at http://www.mhlw.
go.jp/stf/shingi/2r9852000000mlub.html, accessed March 27, 2015
10. Murakami A, Hirata Y, Motomura N, Miyata H, Iwanaka T, Takamoto S. The
national clinical database as an initiative for quality improvement in Japan.
Korean J of Thorac Cardiovasc Surg. 2014;47:437–43.
11. Kimura S, Sato T, Ikeda S, Noda M, Nakayama T. Development of a database
of health insurance claims: standardization of disease classifications and
anonymous record linkage. J Epidemiol. 2010;20:413–9.12. Katada H, Yukawa N, Urushihara H, Tanaka S, Mimori T, Kawakami K.
Prescription patterns and trends in anti-rheumatic drug use based on a
large-scale claims database in Japan. Clin Rheumatol 2014. doi: 10.1007/
s10067-013-2482-1
13. Hashikata H, Harada KH, Kagimura T, Nakamura M, Koizumi A. Usefulness of
a large automated health records database in pharmacoepidemiology.
Environ Health Prev Med. 2011;16:313–9.
14. Takahashi Y, Nishida Y, Asai S. Utilization of health care databases for
pharmacoepidemiology. Eur J Clin Pharmacol. 2012;68:123–9.
15. Inoue D, Kishimoto H. Management of Glucocorticoid-induced or Lifestyle-
related Disease-associated Osteoporosis in University Hospitals in Japan.
J New Rem Clin. 2014;63:1292–301.
16. Hall GC, Sauer B, Bourke A, Brown JS, Revnolds MW, Lo Casale R. Guidelines
for good database selection and use in pharmacoepidemiology research.
Pharmacoepidemiol Drug Saf. 2012;21:1–10.
17. Ministry of Education, Culture, Sports, Science and Technology and Ministry
of Health, Labour and Welfare: The Ethical Guidelines on Biomedical
Research Involving Human Subjects. Available at http://www.lifescience.
mext.go.jp/files/pdf/n1443_01.pdf, Accessed March 27, 2015.
18. Ueyama H, Hinotsu S, Tanaka S, Urushihara H, Nakamura M, Nakamura Y,
et al. Application of a self-controlled case series study to a database study
in children. Drug Saf. 2014;37:259–68.
19. Luce BR, Drummond M, Jonsson B, Neumann PJ, Schwartz JS, Siebert U,
et al. EBM, HTA, and CER: clearing the confusion. Milbank Q. 2010;88:256–76.
20. Onishi Y, Hinotsu S, Nakao YM, Urushihara H, Kawakami K. Economic
evaluation of pravastatin for primary prevention of coronary artery disease
based on risk prediction from JALS-ECC in Japan. Value Health Regional
Issues. 2013;2:5–12.
21. Pharmaceuticals and Medical Devices Agency: Iryou Jouhou no Database tou
wo motiita Iyakuhinn no Annzenseihyouka niokeru Yakuzaiekigakukennkyu no
Jisshi ni kannsuru Guideline. Available at http://www.pmda.go.jp/files/
000157340.pdf, Accessed March 27, 2015.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
